通过封装在β-环素纳米颗粒中控制虫驱虫剂混合物的释放速度
Bernadatte M Ratemo1, Benson M Wachira2,3, Eric Masika1
1Department of Chemistry, Kenyatta University, Nairobi, Kenya.
Journal of nanotechnology
|August 22, 2025
概括
在β-cyclodextrin纳米颗粒中微封装一种防剂混合物,可提供受控释放. 这种技术可以延长防护期,
科学领域:
- 昆虫学
- 寄生虫学
- 材料科学
背景情况:
- 在撒哈拉以南的非洲地区,
- 驱虫剂对于管理种群至关重要.
- 一个先前优化的四组分驱逐剂混合物需要控制释放机制以提高有效性.
研究的目的:
- 探索微封装方法 (化,共同沉,加热,冷干燥) 用于β-cyclodextrin纳米颗粒中的防剂.
- 在实验室和现场环境中评估封装混合物的释放动力学和排斥力.
- 将封装混合物与非封装配方的性能进行比较.
主要方法:
- 使用β-环氧通过,共同沉,加热和冷干燥将四个成分的驱虫剂混合物 (δ-nonalactone,heptanoic acid,4-methylguaiacol,geranyl acetone) 微封装.
- 气色谱-火焰电离探测器 (GC-FID) 分析以确定化合物保留和释放动力学.
- 实验室和现场生物测试,以评估封装和非封装混合物对的排斥力.
主要成果:
- 微封装技术保留了驱虫剂混合物的不同百分比: (72.0%),共同沉 (61.0%),加热 (59.5%) 和冷干燥 (57.3%).
- 囊中的非封装混合物 (6. 7311. 82 mg/ h) 的释放率明显高于制封装混合物 (5. 35 mg/ h).
- 实验室和实地测试证实了封装和非封装混合物的排斥效果,与释放动力学的发现保持一致.
结论:
- 在β-环氧化纳米颗粒中微封装排斥气味可促进活性分子的控制释放.
- 这种技术可以在防治及相关传染昆虫的过程中提供更长的保护期.
- 控制释放配方有可能降低昆虫控制计划的运营成本.
更多相关视频
相关概念视频
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
311
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
311
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
94
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
94
01:23Modified-Release Drug Delivery Systems: Classification
282
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
282
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
112
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
112
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
115
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
115